

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BlissCo Cannabis Corp. (the "Issuer").

Trading Symbol: BLIS

Number of Outstanding Listed Securities: 102,330,171

Date: November 5, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

BlissCo continued to make progress in earning a sales amendment to its license, by responding in a timely manner to Health Canada's request for additional information. The additional information was submitted on October 16th, 2018, ahead of Health Canada's October 22, 2018 submission deadline.

BlissCo continued to work on developing and preparing to launch its telemedicine app and e-commerce website, which are expected to launch in early December 2018.

BlissCo's Quality Assurance Team continued to implement corrective actions in preparation for a Eudralex GMP audit.

BlissCo also continued to prepare for the submission of its application to Health Canada to earn its cannabis oil sales license amendment.

On October 11, 2018 BlissCo announced that it had signed a letter of intent (LOI) to purchase CannaTel Cannabis Corporation ("CannaTel") which has secured pre-approval for a medical cannabis cultivation license in Israel in partnership with local farmer Mr. Yoel Dub. BlissCo will pay \$3,000,000 CAN in BlissCo shares to CannaTel paid in installments tied to specific milestones being met. BlissCo will work in partnership with local farmer Mr. Yoel Dub who has earned a pre-approval for a medical cannabis production license from Israel's Ministry of Health.

2. Provide a general overview and discussion of the activities of management.

BlissCo management has been overseeing and managing the progress of the business and operations described in 1. above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company hired a Quality Assurance Associate, Patient Care team member, Packaging & Sanitation Associate and a Production team member.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

13. Provide details of any securities issued and options or warrants granted.

The Company announced that it has retained Ariel Jack Lewinski to provide business development and investor relations services for a period of three months in exchange for \$10,000 per month and granted 30,000 options at a price of \$0.315 per share, exercisable for a period of three years.

Furthermore, the Company announced that it has granted to its officers, directors and employees an aggregate of 1,100,000 stock options at a price of \$0.315 per share. 300,000 of the stock options are exercisable for a period of three years and the remaining 800,000 of the stock options are exercisable for a period of ten years.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

FORM 7 – MONTHLY PROGRESS REPORT

(1) State aggregate proceeds and intended allocation of proceeds.

14. Provide details of any loans to or by Related Persons.

None

15. Provide details of any changes in directors, officers or committee members.

On October 22nd, the Company appointed Jennifer Archibald as the Company's Chief Financial Officer.

On October 24th, the Company appointed Meena Ballantyne to its Board of Directors.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 5, 2018.

Damian Kettlewell
Name of Director or Senior
Officer

"Damian Kettlewell"
Signature

CEO
Official Capacity

Issuer Details Name of Issuer BlissCo Cannabis Corp	For Month End October 2018	Date of Report YY/MM/D 18/11/05
Issuer Address Suite 2050 – 1055 West Georgia Street,		
City/Province/Postal Code Vancouver, BC, V6E 3P3	Issuer Fax No. (604) 682-4768	Issuer Telephone No. ()
Contact Name Jennifer Archibald	Contact Position CFO	Contact Telephone No. (604) 684-2181